 <h1>Carmustine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to carmustine: implantation implant</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, carmustine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking carmustine:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>change in ability to see colors, especially blue or yellow</li>
<li>confusion</li>
<li>fever</li>
<li>headache</li>
<li>nausea</li>
<li>problems with movement, walking, or speech</li>
<li>seizures</li>
<li>trouble healing</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Change in personality</li>
<li>drowsiness</li>
<li>general feeling of illness</li>
<li>severe headache</li>
<li>stiff neck or back</li>
<li>weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of carmustine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty having a bowel movement</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>frequent urge to urinate</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>lack or loss of strength</li>
<li>loss of interest or pleasure</li>
<li>lower back or side pain</li>
<li>stomach pain</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to carmustine: implant device, intravenous powder for injection</i></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, pulmonary embolism</p>
<p><b>Frequency not reported</b>: Pulmonary toxicity (IV formulation)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Myelosuppression (IV formulation)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, vomiting, constipation</p>
<p><b>Common</b> (1% to 10%): Abdominal pain</p>
<p><b>Postmarketing reports</b>: Diarrhea, anorexia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Increased transaminase, increased alkaline phosphatase, increased bilirubin<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Progressive azotemia, decrease in kidney size, renal failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Tachycardia, chest pain, Veno-occlusive disease<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Administration reactions (IV formulation)</p>
<p><b>Postmarketing reports</b>: Burning sensation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia, fever</p>
<p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Frequency not reported</b>: Wafer migration (wafer formulation)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Ocular toxicity (IV formulation)</p>
<p><b>Postmarketing reports</b>: Conjunctival edema, conjunctival hemorrhage, blurred vision, loss of depth perception<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Postmarketing reports</b>: Acute leukemia, bone marrow dysplasia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Impaired neurosurgical wound healing (wafer formulation) (16%)</p>
<p><b>Common</b> (1% to 10%): Meningitis (wafer formulation)</p>
<p><b>Postmarketing reports</b>: Opportunistic infection (sometimes fatal)</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain</p><h3>Metabolic</h3><p><b>Postmarketing reports</b>: Diabetes mellitus</p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Confusion, depression</p>
<p><b>Common</b> (1% to 10%): Anxiety, thinking abnormal, hallucinations, insomnia, personality disorder</p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection</p><h3>Nervous system</h3><p>(wafer formulation) (23%), aphasia, somnolence, speech disorder</p>
<p><b>Common</b> (1% to 10%): Intracranial hypertension (wafer formulation), brain abscess (wafer formulation), brain cyst (wafer formulation), hydrocephalus (wafer formulation), cerebral edema (wafer formulation), amnesia, facial paralysis, ataxia, hypesthesia, paresthesia, abnormal gait, dizziness, tremor, coma, hypokinesia</p>
<p><b>Postmarketing reports</b>: Headache, encephalopathy</p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p>
<p><b>Postmarketing reports</b>: Hyperpigmentation, swelling, erythema, skin necrosis, alopecia, allergic reaction</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_2">2. O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA "Late carmustine lung fibrosis. Age at treatment may influence severity and survival." Chest 107 (1995): 1355-7</p><p id="ref_3">3. Hasleton PS, O'Driscoll BR, Lynch P, Webster A, Kalra SJ, Gattamaneini HR, Woodcock AA, Poulter LW "Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma." J Pathol 164 (1991): 31-6</p><p id="ref_4">4. Lena H, Desrues B, Le Coz A, Quinquenel ML, Delaval P "Severe diffuse interstitial pneumonitis induced by carmustine (BCNU)." Chest 105 (1994): 1602-3</p><p id="ref_5">5. "Product Information. BiCNU (carmustine)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_6">6. Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP "Myocardial ischemia associated with high-dose carmustine infusion." Cancer 68 (1991): 1910-2</p><p id="ref_7">7. Mrozek-Orlowski M, Christie J, Flamme C, Novak J "Pain associated with peripheral infusion of carmustine." Oncol Nurs Forum 18 (1991): 942</p><p id="ref_8">8. Wiencke JK, Wiemels J "Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." Mutat Res 339 (1995): 91-119</p></div>
<div class="more-resources" id="moreResources">
<h2>More about carmustine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: alkylating agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Carmustine Implantation &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Carmustine Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>BiCNU, Gliadel</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Brain Tumor</li>
<li>Glioblastoma Multiforme</li>
<li>Hodgkin's Lymphoma</li>
<li>Malignant Glioma</li>
<li>Multiple Myeloma</li>
<li>Non-Hodgkin's Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to carmustine: implant device, intravenous powder for injection</i></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, pulmonary embolism</p><p><b>Frequency not reported</b>: Pulmonary toxicity (IV formulation)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Myelosuppression (IV formulation)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, vomiting, constipation</p><p><b>Common</b> (1% to 10%): Abdominal pain</p><p><b>Postmarketing reports</b>: Diarrhea, anorexia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Increased transaminase, increased alkaline phosphatase, increased bilirubin<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Progressive azotemia, decrease in kidney size, renal failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Tachycardia, chest pain, Veno-occlusive disease<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Administration reactions (IV formulation)</p><p><b>Postmarketing reports</b>: Burning sensation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia, fever</p><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Frequency not reported</b>: Wafer migration (wafer formulation)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Ocular toxicity (IV formulation)</p><p><b>Postmarketing reports</b>: Conjunctival edema, conjunctival hemorrhage, blurred vision, loss of depth perception<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Postmarketing reports</b>: Acute leukemia, bone marrow dysplasia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Impaired neurosurgical wound healing (wafer formulation) (16%)</p><p><b>Common</b> (1% to 10%): Meningitis (wafer formulation)</p><p><b>Postmarketing reports</b>: Opportunistic infection (sometimes fatal)</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain</p><h3>Metabolic</h3><p><b>Postmarketing reports</b>: Diabetes mellitus</p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Confusion, depression</p><p><b>Common</b> (1% to 10%): Anxiety, thinking abnormal, hallucinations, insomnia, personality disorder</p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection</p><h3>Nervous system</h3><p>(wafer formulation) (23%), aphasia, somnolence, speech disorder</p><p><b>Common</b> (1% to 10%): Intracranial hypertension (wafer formulation), brain abscess (wafer formulation), brain cyst (wafer formulation), hydrocephalus (wafer formulation), cerebral edema (wafer formulation), amnesia, facial paralysis, ataxia, hypesthesia, paresthesia, abnormal gait, dizziness, tremor, coma, hypokinesia</p><p><b>Postmarketing reports</b>: Headache, encephalopathy</p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p><p><b>Postmarketing reports</b>: Hyperpigmentation, swelling, erythema, skin necrosis, alopecia, allergic reaction</p><p id="ref_1">1. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_2">2. O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA "Late carmustine lung fibrosis. Age at treatment may influence severity and survival." Chest 107 (1995): 1355-7</p><p id="ref_3">3. Hasleton PS, O'Driscoll BR, Lynch P, Webster A, Kalra SJ, Gattamaneini HR, Woodcock AA, Poulter LW "Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma." J Pathol 164 (1991): 31-6</p><p id="ref_4">4. Lena H, Desrues B, Le Coz A, Quinquenel ML, Delaval P "Severe diffuse interstitial pneumonitis induced by carmustine (BCNU)." Chest 105 (1994): 1602-3</p><p id="ref_5">5. "Product Information. BiCNU (carmustine)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_6">6. Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP "Myocardial ischemia associated with high-dose carmustine infusion." Cancer 68 (1991): 1910-2</p><p id="ref_7">7. Mrozek-Orlowski M, Christie J, Flamme C, Novak J "Pain associated with peripheral infusion of carmustine." Oncol Nurs Forum 18 (1991): 942</p><p id="ref_8">8. Wiencke JK, Wiemels J "Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." Mutat Res 339 (1995): 91-119</p><h2>More about carmustine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: alkylating agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Carmustine Implantation &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Carmustine Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Brain Tumor</li>
<li>Glioblastoma Multiforme</li>
<li>Hodgkin's Lymphoma</li>
<li>Malignant Glioma</li>
<li>Multiple Myeloma</li>
<li>Non-Hodgkin's Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>